
Michael Kassiou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5580598/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Boron in Drug Discovery: Carboranes as Unique Pharmacophores in Biologically Active Compounds. Chemical Reviews, 2011, 111, 5701-5722.	23.0	595
2	Small animal SPECT and its place in the matrix of molecular imaging technologies. Physics in Medicine and Biology, 2005, 50, R45-R61.	1.6	286
3	DPA-714, a New Translocator Protein–Specific Ligand: Synthesis, Radiofluorination, and Pharmacologic Characterization. Journal of Nuclear Medicine, 2008, 49, 814-822.	2.8	237
4	Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling, 2020, 13, .	1.6	219
5	Pharmacology of Valinate and <i>tert</i> -Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 2016, 7, 1241-1254.	1.7	214
6	Comparative Evaluation of the Translocator Protein Radioligands ¹¹ C-DPA-713, ¹⁸ F-DPA-714, and ¹¹ C-PK11195 in a Rat Model of Acute Neuroinflammation. Journal of Nuclear Medicine, 2009, 50, 468-476.	2.8	208
7	Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. Neurobiology of Disease, 2015, 74, 58-65.	2.1	208
8	Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e52941.	1.1	203
9	Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 2015, 6, 1546-1559.	1.7	202
10	Evaluation of the PBR/TSPO Radioligand [¹⁸ F]DPA-714 in a Rat Model of Focal Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 230-241.	2.4	184
11	Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain, Behavior, and Immunity, 2011, 25, 1113-1122.	2.0	173
12	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2019, 20, 3161.	1.8	173
13	Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 2015, 6, 1445-1458.	1.7	167
14	Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Molecular Psychiatry, 2018, 23, 323-334.	4.1	159
15	Neuroinflammation in frontotemporal dementia. Nature Reviews Neurology, 2019, 15, 540-555.	4.9	159
16	An overview of late-stage functionalization in today's drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 1137-1149.	2.5	140
17	The Translocator Protein. Journal of Nuclear Medicine, 2011, 52, 677-680.	2.8	139
18	11C-DPA-713: A Novel Peripheral Benzodiazepine Receptor PET Ligand for In Vivo Imaging of Neuroinflammation, Journal of Nuclear Medicine, 2007, 48, 573-581	2.8	137

#	Article	IF	CITATIONS
19	In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [11C]DPA-713 PET and analysis of CSF and plasma. Translational Psychiatry, 2016, 6, e777-e777.	2.4	134
20	Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. JAMA Neurology, 2017, 74, 67.	4.5	134
21	Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography. Current Medicinal Chemistry, 2009, 16, 2899-2923.	1.2	123
22	DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications. , 2015, 151, 87-98.		122
23	Positron emission tomography imaging of neuroinflammation. Neurotherapeutics, 2007, 4, 443-452.	2.1	119
24	The First CNS-Active Carborane: A Novel P2X ₇ Receptor Antagonist with Antidepressant Activity. ACS Chemical Neuroscience, 2014, 5, 335-339.	1.7	118
25	Initial Evaluation of ¹¹ C-DPA-713, a Novel TSPO PET Ligand, in Humans. Journal of Nuclear Medicine, 2009, 50, 1276-1282.	2.8	117
26	Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nuclear Medicine and Biology, 2012, 39, 570-578.	0.3	115
27	[11C]-DPA-713 and [18F]-DPA-714 as New PET Tracers for TSPO: A Comparison with [11C]-(R)-PK11195 in a Rat Model of Herpes Encephalitis. Molecular Imaging and Biology, 2009, 11, 386-98.	1.3	113
28	Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the V1A Receptor. Neuropsychopharmacology, 2013, 38, 2249-2259.	2.8	112
29	Developing a preclinical model of Parkinson's disease: A study of behaviour in rats with graded 6-OHDA lesions. Behavioural Brain Research, 2006, 169, 1-9.	1.2	109
30	Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand. Bioorganic and Medicinal Chemistry, 2005, 13, 6188-6194.	1.4	108
31	Cubanes in Medicinal Chemistry. Journal of Medicinal Chemistry, 2019, 62, 1078-1095.	2.9	97
32	Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. Neuroscience, 2011, 189, 170-177.	1.1	95
33	The Translocator Protein (18 kDa): Central Nervous System Disease and Drug Design. Journal of Medicinal Chemistry, 2009, 52, 581-592.	2.9	92
34	Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration. Molecular Imaging and Biology, 2018, 20, 94-102.	1.3	88
35	Development of Ligands for the Peripheral Benzodiazepine Receptor. Current Medicinal Chemistry, 2006, 13, 1991-2001.	1.2	83
36	The translocator protein (TSPO): A novel target for cancer chemotherapy. International Journal of Biochemistry and Cell Biology, 2013, 45, 1212-1216.	1.2	82

#	Article	IF	CITATIONS
37	The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience, 2013, 4, 1081-1092.	1.7	80
38	Imaging Sigma Receptors: Applications in Drug Development. Current Pharmaceutical Design, 2007, 13, 51-72.	0.9	78
39	Regional brain distribution of translocator protein using [11C]DPA-713 PET in individuals infected with HIV. Journal of NeuroVirology, 2014, 20, 219-232.	1.0	78
40	Detection of the recently emerged synthetic cannabinoid 5F–MDMBâ€PICA in â€~legal high' products and human urine samples. Drug Testing and Analysis, 2018, 10, 196-205.	1.6	78
41	P2X purinergic receptor ligands: recently patented compounds. Expert Opinion on Therapeutic Patents, 2010, 20, 625-646.	2.4	77
42	[18F]DPA-714: Direct Comparison with [11C]PK11195 in a Model of Cerebral Ischemia in Rats. PLoS ONE, 2013, 8, e56441.	1.1	77
43	Radiosynthesis of [¹⁸ F]DPAâ€714, a selective radioligand for imaging the translocator protein (18 kDa) with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2008, 51, 286-292.	0.5	76
44	Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the nonâ€peptide oxytocin receptor agonist <scp>WAY</scp> 267,464: a biotelemetry study in rats. British Journal of Pharmacology, 2014, 171, 2868-2887.	2.7	70
45	Peptides, Peptidomimetics, and Carbohydrate–Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease. ACS Chemical Neuroscience, 2018, 9, 1530-1551.	1.7	70
46	In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET. Journal of Neuroinflammation, 2018, 15, 314.	3.1	64
47	Reduced PBR/TSPO Expression After Minocycline Treatment in a Rat Model of Focal Cerebral Ischemia: A PET Study Using [18F]DPA-714. Molecular Imaging and Biology, 2011, 13, 10-15.	1.3	63
48	The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptorâ€Binding Profile, Prosocial Effects and Distribution of câ€Fos Expression in Adolescent Rats. Journal of Neuroendocrinology, 2012, 24, 1012-1029.	1.2	63
49	Altered proteostasis in aging and heat shock response in C. elegans revealed by analysis of the global and de novo synthesized proteome. Cellular and Molecular Life Sciences, 2014, 71, 3339-3361.	2.4	63
50	Design, Synthesis, and Structureâ^'Affinity Relationships of Regioisomeric <i>N</i> -Benzyl Alkyl Ether Piperazine Derivatives as σ-1 Receptor Ligands. Journal of Medicinal Chemistry, 2010, 53, 6228-6239.	2.9	62
51	In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurologica Scandinavica, 2006, 114, 107-114.	1.0	61
52	Metabolism and Quantification of [¹⁸ F]DPA-714, a New TSPO Positron Emission Tomography Radioligand. Drug Metabolism and Disposition, 2013, 41, 122-131.	1.7	61
53	In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT. Nuclear Medicine and Biology, 2001, 28, 165-175.	0.3	59
54	The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia. CNS Drugs, 2015, 29, 529-542.	2.7	58

#	Article	IF	CITATIONS
55	Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats. Molecular Imaging and Biology, 2017, 19, 77-89.	1.3	58
56	<i>O</i> -GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease. ACS Chemical Neuroscience, 2019, 10, 2209-2221.	1.7	56
57	The evolving science of phytocannabinoids. Nature Reviews Chemistry, 2018, 2, .	13.8	55
58	PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT). Current Topics in Medicinal Chemistry, 2010, 10, 1569-1583.	1.0	54
59	Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. Scientific Reports, 2018, 8, 6580.	1.6	54
60	Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues. ACS Chemical Neuroscience, 2017, 8, 2159-2167.	1.7	53
61	The Fifth Element in Drug Design: Boron in Medicinal Chemistry. Australian Journal of Chemistry, 2013, 66, 1118.	0.5	48
62	Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET. Journal of Neuroinflammation, 2018, 15, 346.	3.1	46
63	In vitro determination of the efficacy of illicit synthetic cannabinoids at CB ₁ receptors. British Journal of Pharmacology, 2019, 176, 4653-4665.	2.7	46
64	Challenges and Opportunities in Central Nervous System Drug Discovery. Trends in Chemistry, 2019, 1, 612-624.	4.4	46
65	Comparison of binding parameters of Ïf1 and Ïf2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes. European Journal of Pharmacology, 1996, 311, 233-240.	1.7	44
66	Recent Advances in the Mitsunobu Reaction: Modifications and Applications to Biologically Active Molecules. Current Organic Chemistry, 2009, 13, 1610-1632.	0.9	44
67	The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 379-389.	3.3	44
68	Effects of Translocator Protein (18 kDa) Ligands on Microglial Activation and Neuronal Death in the Quinolinic-Acid-Injected Rat Striatum. ACS Chemical Neuroscience, 2012, 3, 114-119.	1.7	43
69	Amyloid load and translocator protein 18ÂkDa in APPswePS1-dE9 mice: a longitudinal study. Neurobiology of Aging, 2015, 36, 1639-1652.	1.5	43
70	Targeting the Oxytocin System: New Pharmacotherapeutic Approaches. Trends in Pharmacological Sciences, 2019, 40, 22-37.	4.0	43
71	Molecular Probes for P2X7 Receptor Studies. Current Medicinal Chemistry, 2007, 14, 1505-1523.	1.2	42
72	Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA. ACS Chemical Neuroscience, 2017, 8, 1673-1680.	1.7	42

#	Article	IF	CITATIONS
73	Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. Theranostics, 2021, 11, 6644-6667.	4.6	42
74	Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma. Journal of Medicinal Chemistry, 2017, 60, 2052-2070.	2.9	41
75	Could 18 F-DPA-714 PET imaging be interesting to use in the early post-stroke period?. EJNMMI Research, 2014, 4, 28.	1.1	40
76	Radiosynthesis and pharmacological evaluation of [11C]EMD-95885: a high affinity ligand for NR2B-containing NMDA receptors. Bioorganic and Medicinal Chemistry, 2004, 12, 3229-3237.	1.4	39
77	Ligands for peripheral benzodiazepine binding sites in glial cells. Brain Research Reviews, 2005, 48, 207-210.	9.1	39
78	The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence. Current Pharmaceutical Design, 2012, 18, 884-901.	0.9	39
79	Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in Caenorhabditis elegans. Nature Protocols, 2014, 9, 2237-2255.	5.5	39
80	Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. Bioorganic and Medicinal Chemistry, 2005, 13, 745-753.	1.4	38
81	Improved synthesis of the peripheral benzodiazepine receptor ligand [11C]DPA-713 using [11C]methyl triflate. Applied Radiation and Isotopes, 2006, 64, 570-573.	0.7	37
82	Fluorine-18 Chemistry for PET: A Concise Introduction. Current Radiopharmaceuticals, 2010, 3, 68-80.	0.3	36
83	Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18kDa translocator protein (TSPO). Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5799-5802.	1.0	35
84	Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration by COX-2 inhibition. Brain, Behavior, and Immunity, 2014, 41, 173-181.	2.0	35
85	The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicology, 2016, 34, 286-303.	1.4	35
86	Trishomocubanes: novel σ-receptor ligands modulate amphetamine-stimulated [3H]dopamine release. European Journal of Pharmacology, 2001, 422, 39-45.	1.7	34
87	Cubyl amides: Novel P2X7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3720-3723.	1.0	34
88	Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. Neuroscience Letters, 2016, 631, 24-29.	1.0	34
89	Synthesis, radiosynthesis and In vivo evaluation of 5-[3-(4-Benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[11C]one, as a potent NR1A/2B subtype selective NMDA PET radiotracer. Bioorganic and Medicinal Chemistry, 2003, 11, 5401-5408.	1.4	32
90	Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. Arthritis Research and Therapy, 2014, 16, R70.	1.6	32

#	Article	IF	CITATIONS
91	The Polyphenol Altenusin Inhibits in Vitro Fibrillization of Tau and Reduces Induced Tau Pathology in Primary Neurons. ACS Chemical Neuroscience, 2017, 8, 743-751.	1.7	32
92	Synthesis and cellular uptake of boron-rich pyrazolopyrimidines: exploitation of the translocator protein for the efficient delivery of boron into human glioma cells. Chemical Communications, 2011, 47, 12179.	2.2	31
93	Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. European Journal of Medicinal Chemistry, 2015, 95, 29-34.	2.6	31
94	Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells. Cell Death Discovery, 2021, 7, 81.	2.0	31
95	Synthesis of Biologically Active Seven-Membered-Ring Heterocycles. Synthesis, 2013, 45, 3211-3227.	1.2	30
96	Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X ₇ Receptor Antagonist. ACS Chemical Neuroscience, 2017, 8, 2374-2380.	1.7	30
97	Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of <i>Plasmodium</i> M1 and M17 Aminopeptidases. Journal of Medicinal Chemistry, 2019, 62, 622-640.	2.9	30
98	Pharmacological evaluation of [11C]A-84543: An enantioselective ligand for in vivo studies of neuronal nicotinic acetylcholine receptors. Life Sciences, 1998, 63, PL13-PL18.	2.0	28
99	Synthesis of 6-[18F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4819-4822.	1.0	28
100	Extracellular Loops 2 and 4 of GLYT2 Are Required for N-Arachidonylglycine Inhibition of Glycine Transport. Journal of Biological Chemistry, 2009, 284, 36424-36430.	1.6	27
101	Oxo-bridged isomers of aza-trishomocubane sigma (if) receptor ligands: Synthesis, in vitro binding, and molecular modeling. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 145-148.	1.0	27
102	Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids. Australian Journal of Chemistry, 2015, 68, 4.	0.5	27
103	Synthesis of Usnic Acid Derivatives and Evaluation of Their Antiproliferative Activity against Cancer Cells. Journal of Natural Products, 2019, 82, 1768-1778.	1.5	27
104	Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 2015, 33, 355-366.	1.4	26
105	Longitudinal investigation of neuroinflammation and metabolite profiles in the <scp>APP</scp> _{swe} ė <scp>PS</scp> 1 _{Δe9} transgenic mouse model of Alzheimer's disease. Journal of Neurochemistry, 2018, 144, 318-335.	2.1	26
106	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Scientific Reports, 2020, 10, 13741.	1.6	26
107	Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors. Bioorganic and Medicinal Chemistry, 2005, 13, 3623-3626.	1.4	25
108	Trishomocubanes: Novel σ ligands modulate cocaine-induced behavioural effects. European Journal of Pharmacology, 2007, 555, 37-42.	1.7	25

#	Article	IF	CITATIONS
109	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [¹¹ C]DPA-713 positron emission tomography. Lupus, 2017, 26, 170-178.	0.8	25
110	The development of CNS-active LRRK2 inhibitors using property-directed optimisation. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3690-3696.	1.0	24
111	TSPO as a target for glioblastoma therapeutics. Biochemical Society Transactions, 2015, 43, 531-536.	1.6	24
112	Kinase targets in CNS drug discovery. Future Medicinal Chemistry, 2017, 9, 303-314.	1.1	24
113	Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists. European Journal of Medicinal Chemistry, 2017, 130, 433-439.	2.6	24
114	Structure-metabolism relationships of valine and tert-leucine-derived synthetic cannabinoid receptor agonists: a systematic comparison of the in vitro phase I metabolism using pooled human liver microsomes and high-resolution mass spectrometry. Forensic Toxicology, 2019, 37, 316-329.	1.4	24
115	Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)?. Current Molecular Medicine, 2012, 12, 387-397.	0.6	24
116	Trishomocubanes, a new class of selective and high affinity ligands for the sigma binding site. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 595-600.	1.0	23
117	Insights into Structure-Activity Relationships and CNS Therapeutic Applications of NR2B Selective Antagonists. Current Medicinal Chemistry, 2010, 17, 4166-4190.	1.2	23
118	Radiation Dosimetry and Biodistribution of the TSPO Ligand 11C-DPA-713 in Humans. Journal of Nuclear Medicine, 2012, 53, 330-335.	2.8	23
119	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 2017, 74, 126-138.	2.9	23
120	Anaesthetic-dependent changes in gene expression following acute and chronic exposure in the rodent brain. Scientific Reports, 2020, 10, 9366.	1.6	23
121	Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection. Brain Research Bulletin, 2009, 80, 397-402.	1.4	22
122	Improved accessibility to the desoxy analogues of Δ9-tetrahydrocannabinol and cannabidiol. Tetrahedron Letters, 2013, 54, 52-54.	0.7	22
123	Radiosynthesis of (<i>R</i> , <i>S</i>)â€{ ¹⁸ F]GE387: A Potential PET Radiotracer for Imaging Translocator Protein 18â€kDa (TSPO) with Low Binding Sensitivity to the Human Gene Polymorphism rs6971. ChemMedChem, 2019, 14, 982-993.	1.6	22
124	Ex vivo and in vivo evaluation of (2 <i>R</i> ,3 <i>R</i>)â€5â€[¹⁸ F]â€fluoroethoxy―and fluoropropoxyâ€benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter. Synapse, 2007, 61, 962-970.	0.6	21
125	NEUROPROTECTIVE EFFECTS OF A SELECTIVE <i> N </i> â€METHYLâ€ <scp>d</scp> â€ASPARTATE NR2B RECEPTC ANTAGONIST IN THE 6â€HYDROXYDOPAMINE RAT MODEL OF PARKINSON'S DISEASE. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 1388-1394.	0.9	21
126	Boronated phosphonium salts containing arylboronic acid, closo-carborane, or nido-carborane: synthesis, X-ray diffraction, in vitro cytotoxicity, and cellular uptake. Journal of Biological Inorganic Chemistry, 2010, 15, 1305-1318.	1.1	21

#	Article	IF	CITATIONS
127	N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma ($ f $ receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5289-5292.	1.0	21
128	Lack of neuroinflammation in the HIV-1 transgenic rat: an [18F]-DPA714 PET imaging study. Journal of Neuroinflammation, 2015, 12, 171.	3.1	21
129	Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. Journal of Psychopharmacology, 2017, 31, 757-769.	2.0	21
130	A binge high sucrose diet provokes systemic and cerebral inflammation in rats without inducing obesity. Scientific Reports, 2021, 11, 11252.	1.6	21
131	The translocator protein as a drug target in Alzheimer's disease. Expert Review of Neurotherapeutics, 2014, 14, 439-448.	1.4	20
132	Insight into the Structural Features of TSPO: Implications for Drug Development. Trends in Pharmacological Sciences, 2020, 41, 110-122.	4.0	20
133	Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer. Oncogene, 2020, 39, 5553-5569.	2.6	20
134	WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. Psychopharmacology, 2015, 232, 2659-2667.	1.5	19
135	Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids. European Journal of Medicinal Chemistry, 2019, 180, 291-309.	2.6	19
136	Localization of temporal lobe epileptic foci with iodine-123 iododexetimide cholinergic neuroreceptor single-photon emission computed tomography. Neurology, 1996, 47, 1015-1020.	1.5	18
137	18F-ZW-104: A New Radioligand for Imaging Neuronal Nicotinic Acetylcholine Receptors—In Vitro Binding Properties and PET Studies in Baboons. Journal of Nuclear Medicine, 2009, 50, 1349-1355.	2.8	18
138	Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18) Tj ETQq0	0 0 rgBT /	Overlock 10 1 18
139	Inhibition of human recombinant Tâ€ŧype calcium channels by <i>N</i> â€arachidonoyl 5â€HT. British Journal of Pharmacology, 2012, 167, 1076-1088.	2.7	18
140	Pharmacological evaluation of a Br-76 analog of epibatidine: A potent ligand for studying brain nicotinic acetylcholine receptors. Synapse, 2002, 45, 95-104.	0.6	17
141	Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. Brain Research Bulletin, 2009, 78, 85-90.	1.4	17
142	Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 38-41.	1.0	17
143	Structure–activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 828-830.	1.0	17
144	Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers. PLoS ONE, 2019, 14, e0222844.	1.1	17

#	Article	IF	CITATIONS
145	Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18) Tj ETQq1 1	0.784314 0.6	l rgBT /Ove
146	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. Brain, 2022, 145, 1598-1609.	3.7	17
147	Development of Radioligands for In Vivo Imaging of GABAA-Benzodiazepine Receptors. Mini-Reviews in Medicinal Chemistry, 2004, 4, 909-921.	1.1	16
148	Radiosynthesis andin vivoevaluation of [11C]Ro-647312: a novel NR1/2B subtype selective NMDA receptor radioligand. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 911-920.	0.5	16
149	N-substituted 8-aminopentacyclo[5.4.0.02,6.03,10.05,9]undecanes as Ïf receptor ligands with potential neuroprotective effects. Bioorganic and Medicinal Chemistry, 2013, 21, 6038-6052.	1.4	16
150	Differential activation of G proteinâ€mediated signaling by synthetic cannabinoid receptor agonists. Pharmacology Research and Perspectives, 2020, 8, e00566.	1.1	16
151	Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro. Neuropharmacology, 2021, 187, 108478.	2.0	16
152	The influence of tomograph sensitivity on kinetic parameter estimation in positron emission tomography imaging studies of the rat brain. Nuclear Medicine and Biology, 2000, 27, 617-625.	0.3	15
153	Trishomocubanes: Requirements for Ï f Receptor Binding and Subtype Selectivity. Australian Journal of Chemistry, 2001, 54, 31.	0.5	15
154	The role of positron emission tomography in the discovery and development of new drugs; As studied in laboratory animals. European Journal of Drug Metabolism and Pharmacokinetics, 2004, 29, 1-6.	0.6	15
155	Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions. Behavioural Brain Research, 2008, 190, 14-21.	1.2	15
156	A σ1 receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecan-3-ols (AHDs). Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6053-6058.	1.0	15
157	Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. Biochemical Pharmacology, 2015, 98, 587-601.	2.0	15
158	Detection of Neuroinflammation in a Rat Model of Subarachnoid Hemorrhage Using [18F]DPA-714 PET Imaging. Molecular Imaging, 2016, 15, 153601211663918.	0.7	15
159	Multiâ€modal imaging of longâ€ŧerm recovery postâ€stroke by positron emission tomography and matrixâ€assisted laser desorption/ionisation mass spectrometry. Rapid Communications in Mass Spectrometry, 2018, 32, 721-729.	0.7	15
160	PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [11C]SMW139. Journal of Neuroinflammation, 2020, 17, 300.	3.1	15
161	The novel P2X7 receptor antagonist PKT100 improves cardiac function and survival in pulmonary hypertension by direct targeting of the right ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H183-H191.	1.5	15
162	[11C]A-69024: A potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. Nuclear Medicine and Biology, 1995, 22, 221-226.	0.3	14

#	Article	IF	CITATIONS
163	Ïf-Binding site ligands inhibit K+ currents in rat locus coeruleus neurons in vitro. European Journal of Pharmacology, 1998, 361, 157-163.	1.7	14
164	Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO). European Journal of Medicinal Chemistry, 2015, 93, 392-400.	2.6	14
165	The Formation of Seven-Membered Heterocycles under Mild Pictet–Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines. Journal of Organic Chemistry, 2016, 81, 4883-4889.	1.7	14
166	Human dosimetry and biodistribution of iodine-123-iododexetimide: a SPECT imaging agent for cholinergic muscarinic neuroreceptors. Journal of Nuclear Medicine, 1995, 36, 1332-8.	2.8	14
167	Radiosynthesis of (E)-N-(2-[11C]methoxybenzyl)-3-phenyl-acrylamidine, a novel subnanomolar NR2B subtype-selective NMDA receptor antagonist. Applied Radiation and Isotopes, 2006, 64, 348-354.	0.7	13
168	Water-soluble phosphonium salts containing 1,12-dicarba-closo-dodecaborane(12). Tetrahedron Letters, 2009, 50, 6457-6461.	0.7	13
169	Molecular hybridization of 4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3622-3626.	1.0	13
170	MDMA (â€~Ecstasy'), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. Pharmacology Biochemistry and Behavior, 2016, 150-151, 115-123.	1.3	13
171	First Nondiscriminating Translocator Protein Ligands Produced from a Carbazole Scaffold. Journal of Medicinal Chemistry, 2019, 62, 8235-8248.	2.9	13
172	Synthesis and in vitro evaluation of fluorine-18 benzimidazole sulfones as CB2 PET-radioligands. Organic and Biomolecular Chemistry, 2019, 17, 5086-5098.	1.5	13
173	Synthesis and Binding Studies of Trishomocubanes: Novel Ligands for Ï f Binding Sites. Australian Journal of Chemistry, 1999, 52, 653.	0.5	12
174	(+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. Nuclear Medicine and Biology, 2002, 29, 295-302.	0.3	12
175	Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1297-1300.	1.0	12
176	Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions. Brain Research Bulletin, 2009, 78, 91-96.	1.4	12
177	Structure–activity relationship studies of SEN12333 analogues: Determination of the optimal requirements for binding affinities at α7 nAChRs through incorporation of known structural motifs. European Journal of Medicinal Chemistry, 2015, 95, 277-301.	2.6	12
178	First Demonstration of Positive Allosteric-like Modulation at the Human Wild Type Translocator Protein (TSPO). Journal of Medicinal Chemistry, 2015, 58, 8743-8749.	2.9	12
179	Derivatives of the pyrazolo[1,5- a]pyrimidine acetamide DPA-713 as translocator protein (TSPO) ligands and pro-apoptotic agents in human glioblastoma. European Journal of Pharmaceutical Sciences, 2017, 96, 186-192.	1.9	12
180	Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination. MedChemComm, 2017, 8, 202-210.	3.5	12

#	Article	IF	CITATIONS
181	The chemistry and pharmacology of synthetic cannabinoid SDBâ€006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis, 2018, 10, 1099-1109.	1.6	12
182	Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. Antibiotics, 2020, 9, 523.	1.5	12
183	Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature. Brain, 2020, 143, 1889-1904.	3.7	12
184	DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells. International Journal of Molecular Sciences, 2021, 22, 4011.	1.8	12
185	Preparation of a bromine-76 labelled analogue of epibatidine: a potent ligand for nicotinic acetylcholine receptor studies. Applied Radiation and Isotopes, 2002, 57, 713-717.	0.7	11
186	Acetylenic Pyridines for Use in PET Imaging of Nicotinic Receptors. ChemMedChem, 2007, 2, 54-57.	1.6	11
187	The development of PET radioligands for imaging the translocator protein (18 kDa): What have we learned?. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 501-510.	0.5	11
188	Synthesis and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-Nâ€2-[4-(2-fluoroethoxy)benzyl]piperazine, a novel σ1 receptor PET imaging agent. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6820-6823.	1.0	11
189	7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 ($If2$) receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4059-4063.	1.0	11
190	Exploration of ring size in a series of cyclic vicinal diamines with σ1 receptor affinity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5493-5497.	1.0	11
191	A practical, multigram synthesis of the 2-(2-(4-alkoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (DPA) class of high affinity translocator protein (TSPO) ligands. Tetrahedron Letters, 2012, 53, 3780-3783.	0.7	11
192	The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET). Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 215-224.	0.5	11
193	[¹⁸ F]DPAâ€C5yne, a novel fluorineâ€18â€labelled analogue of DPAâ€714: radiosynthesis and preliminary evaluation as a radiotracer for imaging neuroinflammation with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 410-418.	0.5	11
194	Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1 a receptors. European Journal of Medicinal Chemistry, 2016, 108, 730-740.	2.6	11
195	Pharmacological evaluation of a novel series of urea, thiourea and guanidine derivatives as P2X 7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2439-2442.	1.0	11
196	New-generation azaindole-adamantyl-derived synthetic cannabinoids. Forensic Toxicology, 2019, 37, 350-365.	1.4	11
197	Synthesis of 3-[(1-[11C]methyl-2(S)-pyrrolidinyl) methoxy]pyridine and 3-[(1-[11C]methyl-2(R)-pyrrolidinyl) methoxy]pyridine: Radioligands for in vivo studies of neuronal nicotinic acetylcholine receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 1997, 39, 425-431.	0.5	10
198	Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as radioligands for the serotonin transporter. Nuclear Medicine and Biology, 2003, 30, 741-746.	0.3	10

#	Article	IF	CITATIONS
199	Sequential 123I-iododexetimide scans in temporal lobe epilepsy: comparison with neuroimaging scans (MR imaging and 18F-FDG PET imaging). European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 180-185.	3.3	10
200	Decreased vesicular acetylcholine transporter and α4β2 nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning. Neuroscience Letters, 2007, 415, 97-101.	1.0	10
201	Purinergic P2X7 receptor antagonists: Chemistry and fundamentals of biological screening. Bioorganic and Medicinal Chemistry, 2009, 17, 4861-4865.	1.4	10
202	CNS cell type–specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. Journal of Biological Chemistry, 2019, 294, 14149-14162.	1.6	10
203	O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on α-synuclein aggregation. Bioorganic Chemistry, 2020, 94, 103389.	2.0	10
204	Radiosynthesis of (±)-1-(2-bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-[11C]-methyl-l,2,3,4-tetrahydro-isoquinoline, [11C]A-69024: A non-benzazepine antagonist for studying dopamine D1 receptors In vivo using PET. Journal of Labelled Compounds and Radiopharmaceuticals, 1994, 34, 431-437.	0.5	9
205	lodine-123N- methyl-4-iododexetimide: a new radioligand for single-photon emission tomographic imaging of myocardial muscarinic receptors. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 339-345.	2.2	9
206	Radiosynthesis of [1231]N-methyl-4-iododexetimide and [1231]N-methyl-4-iodolevetimide: In vitro and in vivo characterisation of binding to muscarinic receptors in the rat heart. Nuclear Medicine and Biology, 1996, 23, 147-153.	0.3	9
207	A practical synthesis of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane. Tetrahedron Letters, 2013, 54, 5345-5347.	0.7	9
208	Novel Furan-2-yl-1 <i>H</i> -pyrazoles Possess Inhibitory Activity against α-Synuclein Aggregation. ACS Chemical Neuroscience, 2020, 11, 2303-2315.	1.7	9
209	The Recent Development of α ₇ Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases. Current Pharmaceutical Design, 2016, 22, 2134-2151.	0.9	9
210	Senolytics: A Novel Strategy for Neuroprotection in ALS?. International Journal of Molecular Sciences, 2021, 22, 12078.	1.8	9
211	Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?. , 2022, 237, 108228.		9
212	Synthesis and stereochemical assignment of heterocycles derived from (2S*,2'S*,4R*,4'R*,6S*,6'S*)-4,4',6,6'-tetramethylperhydro-2,2'-bipyrimidine. Journal of Organic Chemistry, 1992, 57, 3901-3905.	1.7	8
213	Synthesis of [76Br]4-bromodexetimide and [76Br]4-bromolevetimide: Radiotracers for studying muscarinic cholinergic receptors using PET. Journal of Labelled Compounds and Radiopharmaceuticals, 1995, 36, 259-266.	0.5	8
214	Effects of streptozotocin-induced diabetes on neuronal sigma receptors in the rat brain. Life Sciences, 1999, 65, PL281-PL286.	2.0	8
215	Pharmacological evaluation of (S)-8-[123I]iodobretazenil: a radioligand for in vivo studies of central benzodiazepine receptors. Nuclear Medicine and Biology, 2003, 30, 191-198.	0.3	8
216	Editorial [Hot Topic: Molecular Imaging in Drug Development (Executive Editor: M. Kassiou)]. Current Pharmaceutical Design, 2007, 13, 1-1.	0.9	8

#	Article	IF	CITATIONS
217	Pyrazolo[1,4]diazepines as non-peptidic probes of the oxytocin and vasopressin receptors. Tetrahedron Letters, 2014, 55, 4568-4571.	0.7	8
218	Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. Pharmacological Research, 2018, 134, 166-178.	3.1	8
219	In vitro and in vivo characterisation of [3H]ANSTO-14 binding to the σ1 binding sites. Nuclear Medicine and Biology, 1999, 26, 209-215.	0.3	7
220	Synthesis and Radiolabelling of Ipratropium and Tiotropium for Use as PET Ligands in the Study of Inhaled Drug Deposition. Australian Journal of Chemistry, 2006, 59, 53.	0.5	7
221	High-resolution imaging of the large non-human primate brain using microPET: a feasibility study. Physics in Medicine and Biology, 2007, 52, 6627-6638.	1.6	7
222	Challenges in molecular imaging of Parkinson's disease: A brief overview. Brain Research Bulletin, 2009, 78, 105-108.	1.4	7
223	Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N′-(methoxyphenylalkyl)piperazine σ1 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5707-5710.	1.0	7
224	Consequences of linker length alteration of the α7 nicotinic acetylcholine receptor (nAChR) agonist, SEN12333. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2380-2384.	1.0	7
225	Recent Advances in the Development of Sigma-1 Receptor Ligands. Australian Journal of Chemistry, 2015, 68, 600.	0.5	7
226	Ring-opened aminothienopyridazines as novel tau aggregation inhibitors. MedChemComm, 2017, 8, 1275-1282.	3.5	7
227	Rapid access to N-(indol-2-yl)amides and N-(indol-3-yl)amides as unexplored pharmacophores. Organic and Biomolecular Chemistry, 2017, 15, 576-580.	1.5	7
228	The role of polycyclic frameworks in modulating P2X7 receptor function. Tetrahedron, 2018, 74, 1207-1219.	1.0	7
229	Synthesis and evaluation of various heteroaromatic benzamides as analogues of –ylidene-benzamide cannabinoid type 2 receptor agonists. Tetrahedron Letters, 2019, 60, 151019.	0.7	7
230	Evaluation of ¹⁸ F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration <i>in vivo</i> in rodents and in human tissue. Theranostics, 2020, 10, 7938-7955.	4.6	7
231	Evidence for equatorial bridging in 2,2'-bis(hexahydropyrimidines), perhydro-4,5,8a,9a-tetraazafluorenes, and perhydro-3a,4a,7a,8a-tetraazacyclopentanofluorenes through one-bond carbon-hydrogen coupling. Journal of Organic Chemistry, 1991, 56, 4308-4312.	1.7	6
232	Preferred Equatorial Linkages of Hexahydropyrimidine Rings in Dodecahydro-2,2'-bipyrimidines. Australian Journal of Chemistry, 1991, 44, 143.	0.5	6
233	Reactions of perhydro-2,2'-bipyrimidines with carbonyl compounds bearing .alphacarbonyl functionality. Journal of Organic Chemistry, 1993, 58, 5753-5758.	1.7	6
234	Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2654-2657.	1.0	6

#	Article	IF	CITATIONS
235	Dopamine D1 Receptor Imaging in the Rodent and Primate Brain Using the Isoquinoline (+)-[11C]A-69024 and Positron Emission Tomography. Journal of Pharmaceutical Sciences, 2008, 97, 2811-2819.	1.6	6
236	Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors. European Journal of Medicinal Chemistry, 2018, 143, 1644-1656.	2.6	6
237	Flexible Analogues of Azaindole DYRK1A Inhibitors Elicit Cytotoxicity in Glioblastoma Cells. Australian Journal of Chemistry, 2018, 71, 789.	0.5	6
238	The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist. European Journal of Medicinal Chemistry, 2021, 210, 113087.	2.6	6
239	Synthesis and evaluation of halogenated dibenzodiazepines as muscarinic receptor ligands. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 799-804.	1.0	5
240	(E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter. Nuclear Medicine and Biology, 2007, 34, 967-971.	0.3	5
241	Synthesis and In-Vivo Evaluation of [11C]p-PVP-MEMA as a PET Radioligand for Imaging Nicotinic Receptors. Australian Journal of Chemistry, 2008, 61, 438.	0.5	5
242	Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease. Current Bioactive Compounds, 2010, 6, 129-155.	0.2	5
243	Synthesis and Biological Evaluation of Adenosines with Heterobicyclic and Polycyclic <i>N</i> ⁶ ubstituents as Adenosine A ₁ Receptor Agonists. ChemMedChem, 2012, 7, 1191-1201.	1.6	5
244	Radiopharmaceuticals for PET imaging of neuroinflammation. Medecine Nucleaire, 2016, 40, 72-81.	0.2	5
245	Remarkable Enhancement in Boron Uptake Within Glioblastoma Cells With Carboranyl–Indole Carboxamides. Chemistry - an Asian Journal, 2018, 13, 3321-3327.	1.7	5
246	Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A. Bioorganic and Medicinal Chemistry, 2018, 26, 5852-5869.	1.4	5
247	Pharmacological characterization of a structural hybrid P2X7R antagonist using ATP and LL-37. European Journal of Pharmacology, 2022, 914, 174667.	1.7	5
248	Purinergic P2X ₇ Receptor: A Therapeutic Target in Amyotrophic Lateral Sclerosis. ACS Chemical Neuroscience, 2022, 13, 1479-1490.	1.7	5
249	Unexpected formation of 5,12-dimethyl-3,7,10,14,15,16-tetraazapentacyclo[7.5.1.12,8.15,16.112,15]octadecane, a novel caged nitrogen heterocycle, and preparation and X-ray crystal structure of its copper(II)chloride complex. Journal of the Chemical Society Chemical Communications, 1991 607.	2.0	4
250	Pharmacological characterization and positron emission tomography evaluation of 4-[76Br]bromodexetimide and 4-[76Br]bromolevetimide for investigations of central muscarinic cholinergic receptors. Nuclear Medicine and Biology, 1996, 23, 235-243.	0.3	4
251	Synthesis of iodine-123 labelled analogues of the partial agonist (S)- and (R)-bretazenil for the study of CNS benzodiazepine receptors using SPECT. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38, 835-845.	0.5	4
252	Carborane-Containing Hydroxyamidine Scaffolds as Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 (IDO1). Australian Journal of Chemistry, 2015, 68, 1866.	0.5	4

#	Article	IF	CITATIONS
253	Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists. European Journal of Medicinal Chemistry, 2017, 136, 330-333.	2.6	4
254	Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphism. European Journal of Medicinal Chemistry, 2020, 207, 112725.	2.6	4
255	Reversing binding sensitivity to A147T translocator protein. RSC Medicinal Chemistry, 2020, 11, 511-517.	1.7	4
256	Synthesis of 7,7′-Linked-bis-Indoles via 7-Tryptamines. Heterocycles, 2016, 93, 333.	0.4	4
257	Synthesis of iodine-123 labelled analogues of imidazenil and ethyl-imidazenil for studying benzodiazepine receptors using SPECT. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38, 1121-1132.	0.5	3
258	Radiosynthesis of bromine-76 and iodine-123 labelled enantiomers of A-69024: radioligands for dopamine D1 receptor studies using PET and SPECT. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 339-346.	0.5	3
259	Pharmacological evaluation of (+)-2-[1231]A-69024 A radioligand for in vivo studies of dopamine D1 receptors. Life Sciences, 2001, 69, 669-675.	2.0	3
260	3-Pyridyl ethers as SPECT radioligands for imaging nicotinic acetylcholine receptors. Applied Radiation and Isotopes, 2004, 60, 669-676.	0.7	3
261	Influence of Trishomocubanes on Sigma Receptor Binding of N-(1-Benzylpiperidin-) Tj ETQq1 1 0.784314 rgBT /Ov	verlock 10 0.7	Тƒ 50 422 Т
262	A patent review of oxytocin receptor antagonists 2013-2017. Expert Opinion on Therapeutic Patents, 2017, 27, 1287-1290.	2.4	3
263	Novel plasma protein binding analysis method for a PET tracer and its radiometabolites: A case study with [11C]SMW139 to explain the high uptake of radiometabolites in mouse brain. Journal of Pharmaceutical and Biomedical Analysis, 2022, 219, 114860.	1.4	3
264	Strategies for targeting the P2Y12 receptor in the central nervous system. Bioorganic and Medicinal Chemistry Letters, 2022, 71, 128837.	1.0	3
265	Synthesis and stereochemical assignment of 2,5-trans-2′,5′-trans-5,5′-dimethylperhydro-2,2′-bipyrimid and heterocycles derived from its condensation with formaldehyde. Tetrahedron, 1994, 50, 2497-2506.	ine 1.0	2
266	[3H]A-69024: A non-benzazepine ligand for in vitro and in vivo studies of dopamine d1 receptors. Life Sciences, 1995, 57, PL367-PL372.	2.0	2
267	In vitro pharmacological properties of 4-bromodexetimide for muscarinic receptors. Life Sciences, 1996, 58, PL337-PL344.	2.0	2
268	X-Ray Crystallographic Structures of Biologically Active Trishomocubanes of the Types Pentacyclo[5.4.0.02,6.03,10.05,9]undecylamines and 4-Azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecane. Australian Journal of Chemistry, 2000, 53, 899.	0.5	2
269	Attenuation correction for the large non-human primate brain imaging using microPET. Physics in Medicine and Biology, 2010, 55, 2351-2363.	1.6	2
270	Investigations of amide bond variation and biaryl modification in analogues of α7 nAChR agonist SEN12333. European Journal of Medicinal Chemistry, 2014, 84, 200-205.	2.6	2

#	Article	IF	CITATIONS
271	A systematic exploration of the effects of flexibility and basicity on sigma ($\ddot{i}f$) receptor binding in a series of substituted diamines. Organic and Biomolecular Chemistry, 2016, 14, 9388-9405.	1.5	2
272	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. European Journal of Pharmacology, 2021, 902, 174098.	1.7	2
273	P2X7 in Bipolar and Depressive Disorders. , 2014, , 635-661.		2
274	TSPO PET Imaging as a Biomarker of Neuroinflammation in Neurodegenerative Disorders. Neuromethods, 2022, , 407-427.	0.2	2
275	11-{[2-(3-Fluorophenyl)ethyl](methyl)amino}pentacyclo[5.4.0.02,6.03,10.05,9]undecan-8-one. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o2693-o2693.	0.2	1
276	117.2 Translational Evaluation of Translocator Protein (TSPO) as a Marker of Neuroinflammation in Schizophrenia. Schizophrenia Bulletin, 2017, 43, S64-S64.	2.3	1
277	Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells. RSC Medicinal Chemistry, 2021, 12, 1910-1925.	1.7	1
278	Cannabis and Cannabinoids. Australian Journal of Chemistry, 2021, 74, 367.	0.5	1
279	Adventures in Translocation: Studies of the Translocator Protein (TSPO) 18 kDa*. Australian Journal of Chemistry, 2021, , .	0.5	1
280	Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant. PLoS ONE, 2022, 17, e0254296.	1.1	1
281	A study of myocardial muscarinic receptors in streptozotocin-induced diabetic rats using iodine-123 N -methyl-4-iododexetimide. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 743-749.	3.3	0
282	KINETIC MODELLING OF NICOTINIC ACETYLCHOLINE RECEPTORS WITH 5-[1231]IODO-A-85380 AND DYNAMIC SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2002, 35, 121-126.	0.4	0
283	Quantification of 5-[123 I]IODO-A-85380 in nonhuman primates using SPECT: Parameter identifiability and stability. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2003, 36, 185-190.	0.4	0
284	Editorial [Hot Topic: Capabilities of PET and SPECT in Pre-Clinical and Clinical Research (Executive) Tj ETQq0 0 0 r	gBT /Over	lock 10 Tf 50
285	(1R,2S,3R,6S,7R,8S)-Tricyclo[6.2.1.02,7]undeca-4,9-diene-3,6-diol. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, 092-093.	0.2	0
286	Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)?. Current Molecular Medicine, 2012, 12, 387-397.	0.6	0
287	OP0235â€Pet high affinity translocator protein ligands as a novel modality for macrophage targeting in arthritis. Annals of the Rheumatic Diseases, 2013, 71, 135.2-135.	0.5	0
288	SAT0558â€New Generation Translocator Protein Pet Tracers To Image Arthritis by Macrophage Targeting in Rheumatoid Arthritis Patients: A Proof of Concept Study:. Annals of the Rheumatic Diseases, 2016, 75,	0.5	0

^{871.2-871.}

#	Article	IF	CITATIONS
289	Efficient radiosynthesis of a [18F]-phosphonium salt containing closo-carborane. Tetrahedron Letters, 2017, 58, 4367-4371.	0.7	0
290	Measuring Affinity of Ligands to the Oxytocin Using. Methods in Molecular Biology, 2022, 2384, 231-245.	0.4	0
291	Editorial [Hot topic: (Part I) Focus on [18F]fluoride Radiochemistry (Guest Editors: D. Roeda, M.) Tj ETQq1 1 0.784	1314 rgBT 0.3	/ <mark>8</mark> verlock
292	IL-1b release and pore formation induced by the human antimicrobial peptide LL-37 may be P2Y13 receptor-mediated. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-41.	0.0	0
293	Pharmacological exploration of peptide ligands with short residence-time at the oxytocin receptor. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-74.	0.0	0
294	Pyrazolo[1, 4]diazepine-based small molecule oxytocin receptor partial agonists. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-24.	0.0	0
295	In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. FASEB Journal, 2019, 33, lb384.	0.2	0